Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MYO5
- Development stage
- Preclinical
- Lead developer
- Myocea
- Modality
- Small Molecules
01
Overview
MYO5 is a preclinical **small molecule** drug candidate from **Myocea** being developed for **spinal muscular atrophy**. In the company's pipeline, MYO5 is associated with **actin polymerization** as its intended biological target area, suggesting a muscle-biology and cytoskeletal modulation approach aimed at improving SMA-relevant skeletal muscle or neuromuscular function. Publicly available information appears limited to pipeline-level disclosure, and no formal brand name, dosage form, route of administration, or detailed binding and pharmacology data have been disclosed.
- Other names
- Myocea-Actin polymerization-small molecule-Spinal Muscular Atrophy
Beyond the preview
Go deeper on MYO5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MYO5.